ClinofibrateHMGCR inhibitor CAS# 30299-08-2 |
- Pemirolast potassium
Catalog No.:BCC4532
CAS No.:100299-08-9
- Desloratadine
Catalog No.:BCC4540
CAS No.:100643-71-8
- Clemastine Fumarate
Catalog No.:BCC4528
CAS No.:14976-57-9
- Hydroxyzine 2HCl
Catalog No.:BCC4519
CAS No.:2192-20-3
- Loratadine
Catalog No.:BCC1262
CAS No.:79794-75-5
- Brompheniramine hydrogen maleate
Catalog No.:BCC4515
CAS No.:980-71-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 30299-08-2 | SDF | Download SDF |
| PubChem ID | 2787 | Appearance | Powder |
| Formula | C28H36O6 | M.Wt | 468.58 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | S-8527 | ||
| Solubility | DMSO : ≥ 30 mg/mL (64.02 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[4-[1-[4-(2-carboxybutan-2-yloxy)phenyl]cyclohexyl]phenoxy]-2-methylbutanoic acid | ||
| SMILES | CCC(C)(C(=O)O)OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(C=C3)OC(C)(CC)C(=O)O | ||
| Standard InChIKey | BMOVQUBVGICXQN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.In Vivo:Clinofibrate administration (50 and 100 mg/kg/day, p.o.) significantly inhibits the increase in plasma fibrinogen level as well as serum- and VLDL-LDL-lipids[1]. Clinofibrate significantly decreases the high plasma cholesterol level of atherosclerotic rats, which is 823±256 mg/dl, or about ten times that of control rats (85±11 mg/dl). On treatment with clinofibrate, the cholesterol level is reduced most in the very low density lipoprotein (VLDL) fraction[2]. In rats which are refed either a fat-free diet or a 5% fat diet after a 2-day fast. clinofibrate at 30 mg/kg results in reductions of serum and liver triglyceride levels[3]. Oral ingestion of S-8527 to normal rats for 7 days lowers serum triglycerides and cholesterol by about 27% at 1 mg/kg and 20% at 3 mg/kg, respectively. S-8527 at 3 mg/kg decreases liver triglyceride concentration by about 20%[4]. References: | |||||
Clinofibrate Dilution Calculator
Clinofibrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1341 mL | 10.6705 mL | 21.3411 mL | 42.6821 mL | 53.3527 mL |
| 5 mM | 0.4268 mL | 2.1341 mL | 4.2682 mL | 8.5364 mL | 10.6705 mL |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1341 mL | 4.2682 mL | 5.3353 mL |
| 50 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 0.8536 mL | 1.0671 mL |
| 100 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.4268 mL | 0.5335 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM, is a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.
- 2-Amino-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide
Catalog No.:BCC8551
CAS No.:302964-24-5
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Ro 67-4853
Catalog No.:BCC7921
CAS No.:302841-89-0
- Ro 01-6128
Catalog No.:BCC7922
CAS No.:302841-86-7
- Ciliobrevin A
Catalog No.:BCC3939
CAS No.:302803-72-1
- TCS 46b
Catalog No.:BCC7482
CAS No.:302799-86-6
- 3,4,5-Trimethoxycinnamyl alcohol
Catalog No.:BCN5212
CAS No.:30273-62-2
- Bisline
Catalog No.:BCN2062
CAS No.:30258-28-7
- Rosiglitazone HCl
Catalog No.:BCC2269
CAS No.:302543-62-0
- Potassium 7-hydroxynaphthalene-1-sulfonate
Catalog No.:BCN8289
CAS No.:30252-40-5
- 1-Hydroxybaccatin I
Catalog No.:BCN5211
CAS No.:30244-37-2
- Ingenol
Catalog No.:BCN2333
CAS No.:30220-46-3
- Heliotrine
Catalog No.:BCN1982
CAS No.:303-33-3
- Lasiocarpine
Catalog No.:BCN2001
CAS No.:303-34-4
- Methenolone enanthate
Catalog No.:BCC9029
CAS No.:303-42-4
- Gossypol
Catalog No.:BCN2702
CAS No.:303-45-7
- Ochratoxin A
Catalog No.:BCC7008
CAS No.:303-47-9
- Coenzyme Q10
Catalog No.:BCN5954
CAS No.:303-98-0
- Pandamarilactonine A
Catalog No.:BCN5213
CAS No.:303008-80-2
- Pandamarilactonine B
Catalog No.:BCN5214
CAS No.:303008-81-3
- Picrasin B acetate
Catalog No.:BCN5215
CAS No.:30315-04-9
- TAK-715
Catalog No.:BCC3968
CAS No.:303162-79-0
- Centrolobol
Catalog No.:BCN5216
CAS No.:30359-01-4
- Dalbergioidin
Catalog No.:BCN4801
CAS No.:30368-42-4
High-performance liquid chromatographic method for determination of clinofibrate and its application to a pharmacokinetic study in healthy volunteers.[Pubmed:23319135]
J Pharm Biomed Anal. 2013 Mar 25;76:152-6.
A convenient and rapid HPLC method was developed for the determination of Clinofibrate in human plasma using simple protein precipitation with the mixture of acetonitrile and 1M hydrochloric acid (95:5, v/v) followed by separation using an Inspire C(18) column with isocratic elution. The detection wavelength was 232nm and the flow rate was 1.0ml/min. The mobile phase consisted of acetonitrile and water containing 0.4% ortho-phosphoric acid (73:27, v/v). Linear calibration curve was obtained over the concentrations ranging from 0.5mug/ml to 32mug/ml (r(2)=0.999) with LLOQ of 0.5mug/ml. The RSD in both the intra-run and inter-run precision study was less than 5.4% and the extraction recoveries were above 90.7%. The HPLC method is reproducible and suitable for the quantification of Clinofibrate in plasma. This method was successfully applied to the pharmacokinetic studies of Clinofibrate in healthy volunteers. The elimination half-lives (t(1/2)) were (20.47+/-3.44), (18.19+/-2.62) and (21.51+/-4.78)h after single oral administration of 200, 400 and 600mg Clinofibrate, respectively. The results of WinNonlin software showed that the area under the plasma concentration versus time curve from time 0 to 72h (AUC(0-72)) and peak plasma concentration (C(max)) were linearly related to dose (P>0.05).
Effects of clinofibrate on plasma fibrinogen level in high fructose diet-induced hyperlipidemic rats.[Pubmed:7772737]
In Vivo. 1994 Nov-Dec;8(6):1057-61.
Effects of Clinofibrate on the coagulative and fibrinolytic activity in an intrinsic hyperlipidemia induced by a cholesterol free-high fructose diet (HFD) for 14 days were studied using male Wistar rats. There were significant and positive correlations between plasma fibrinogen level and serum lipid content, and between fibrinogen level and VLDL-LDL-lipid content. Clinofibrate administration (50 and 100 mg/kg/day, p.o.) significantly inhibited the increase in plasma fibrinogen level as well as serum- and VLDL-LDL-lipids. It is concluded that Clinofibrate, in addition to its beneficial effect on the serum lipid profile, can effectively reduce the plasma fibrinogen level.
Development of a LC-MS/MS method for the estimation of clinofibrate in human urine.[Pubmed:26012250]
Pharmazie. 2015 Apr;70(4):219-24.
A highly sensitive and rapid liquid chromatography-tandem mass spectrometry method was developed for the determination of Clinofibrate in human urine. The analyte and IS were extracted through a simple protein precipitation by the mixture of acetonitrile and 1 mol/L hydrochloric acid (95:5, v/v) and separated on an Inspire C18 (150 mm x 4.6 mm I.D., 5 mum particle size) column using isocratic elution with methanol and water containing 0.1% formic acid and 10 mM ammonium acetate (90:10, v/v). Mass spectrometric detection was performed in electrospray positive ionization MRM mode. The mass transition was m/z 486.3-->175.0 for Clinofibrate and m/z 361.1-->233.1 for IS, respectively. The flow rate was 0.6 mL/min and the column oven temperature was set at 35 degrees C. The total run time was 6.5 min. Good linear relationships were obtained for all analytes over the concentrations ranging of 0.1002-10.02 mug/mL (r2 = 0.9991) and the limit of quantification was 0.1002 mug/mL. The extraction recovery was larger than 87.4% and intra- and inter-batch precision and accuracy with RSD were all less than 6.5%. The total amount of unchanged Clinofibrate excreted in urine was less than 0.34%. This method was successfully applied to the pharmacokinetic study of Clinofibrate in human urine.
Effect of food on the single-dose pharmacokinetics and tolerability of clinofibrate tablets in Chinese healthy volunteers.[Pubmed:23849436]
Int J Clin Pharmacol Ther. 2013 Aug;51(8):672-7.
The aim of this study is to investigate a food effect on the single-dose pharmacokinetics and tolerability of Clinofibrate tablets in 12 Chinese healthy volunteers. The authors evaluated the effect of being under a fasting or fed state at the time of drug intake on the single-dose of Clinofibrate 400 mg tablets in a randomized, balanced, single-dose, two-treatment (fed and fasting), two-period, two-sequence study design with a 7-day washout period. The end points were the maximum plasma drug concentration (Cmax) and areas under the plasma-concentration curve (AUC) for 72 hours exposure (AUC0-72) and total exposure (AUC0-infinity). All participants completed the whole study without side effects being observed. The Cmax mean of Clinofibrate glucuronides and parent Clinofibrate were 21.91, 17.85 mu/ml for the fasting state and 13.14, 11.25 mu/ml for the fed state, respectively. The AUC0-72 and AUC0-infinity of Clinofibrate glucuronides and parent Clinofibrate were 381.60, 307.07 mu/ ml and 404.55, 342.24 mu/ml for the fasting state and 379.02, 321.14 mu/ml and 432.24, 351.80 mu/ml for the fed state. The authors showed that food intake was associated with a significant decrease in Cmax, but no significant change in AUC values.
